Related Experiment Video

Updated: Jul 31, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

[Preventive effect of TJ-48 on recovery from radiation injury]

Y Ohnishi1, R Yasumizu, S Ikehara

  • 1First Dept. of Pathology, Kansai Medical University.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|April 1, 1989
PubMed

Effects of Juzen-taiho-toh (TJ-48) on the recovery of haemopoietic systems from radiation injury are analyzed. Female C57BL/6 mice (6 to 8 week-old) were irradiated at doses of 0, 1, 2, 3, 5 or 7 Gy from a 60Co source. During the 7 days after irradiation, the mice were given TJ-48 solution (1.25g in 100ml distilled water). Seven days after irradiation, the mice were sacrificed, and cell counts of bone marrow (both femurs), thymus, spleen, and peripheral blood were made. The bone marrow cells were used for CFU-f, CFU-GM, BFU-E, and CFU-E assays. No difference were observed between the experimental and control groups. However, the CFU-S. d14 and CFU-S.d9 counts in the TJ-48-treated groups were greater than the respective values in the control groups, especially in the low-dose range of irradiation (1, 2, 3 Gy). In the assay for CFU-S.d14, the mice injected with TJ-48-treated bone marrow cells showed better general condition, heavier spleens with larger and more numerous colonies than the control mice. There was no difference in the number of CFU-f between TJ-48-treated and control groups. Since the CFU-S.d14 assay is thought to reflect the most primitive progenitor cells in the haemopoietic system, these results strongly suggest that TJ-48 acts on stem cells in the G0 phase to manifest recovery-enhancing effects from radiation injury.

More Related Videos

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Related Concept Videos

Biological Effects of Radiation02:59

Biological Effects of Radiation

All radioactive nuclides emit high-energy particles or electromagnetic waves. When this radiation encounters living cells, it can cause heating, break chemical bonds, or ionize molecules. The most serious biological damage results when these radioactive emissions fragment or ionize molecules. For example, α and β particles emitted from nuclear decay reactions possess much higher energies than ordinary chemical bond energies. When these particles strike and penetrate matter, they produce ions...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.